Pembrolizumab extends survival in recurrent head and neck cancer
A study of nearly 500 patients with head and neck cancers reveals that pembrolizumab could extend survival compared with methotrexate, docetaxel or cetuximab, which are the standard of care.
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Docetaxel | Drugs & Pharmacology | Erbitux | Head and Neck Cancer | Methotrexate | Study | Taxotere